Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 2447

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 9B
Chunk 2447
---
 from issuance of common stock through exercise of warrants 
     365  
     - 
  
    Proceeds from long term loan 
     11,324  
     15,818 
  
    Payment of loan 
     (18,052) 
     (835)
  
    Net cash provided by financing activities 
     16,646  
     43,167 
  
    Effect of exchange rate changes on cash and cash equivalents 
     (45) 
     (77)

    Decrease in cash, cash equivalents and restricted cash 
     (6,712) 
     (25,160)
  
    Cash, cash equivalents and restricted cash at beginning of year 
     11,608  
     36,768 
  
    Cash, cash equivalents and restricted cash at end of year 
    $4,896  
    $11,608 
  
    Supplemental disclosure of non-cash investing and financing activities: 

    Debt discount 
    $3,249  
    $4,541 
  
    End of term loan liability 
    $-  
    $(613)
  
    Warrant liability 
    $-  
    $(885)
  
    Derivative liability 
    $-  
    $(1,361)
  
    Short term finance liability 
    $693  
    $740 
  
    Fixed assets recorded in accounts payable and accrued expenses 
    $396  
    $404 
  
    Interest paid 
    $1,197  
    $1,759 
  
    Income taxes paid 
    $-  
    $- 

The
accompanying notes are an integral part of these consolidated financial statements.

F-8

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE
1 ORGANIZATION AND BUSINESS

Beyond
Air, Inc. (together with its subsidiaries, “Beyond Air” or the “Company”) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company’s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.

The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators
and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. The Company